Please login to the form below
overactive bladder
This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.
Urovant slips on phase 3 incontinence drug data
The phase 3 EMPOWUR trial of vibegron in patients with incontinence caused by overactive bladder (OAB) showed that the beta-3 adrenergic agonist performed significantly better than placebo on the two
Latest news
-
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... There are no currently available FDA-approved gene therapy treatments for overactive bladder.
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
The proceeds will fund phase III trials of its overactive bladder treatment candidate vibegron, which it in-licensed last year from Merck &Co. ... Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB
-
Allergan pushes on with Botox for depression
overactive in depression. ... Aside from its use as a wrinkle treatment Botox is already approved to treat various medical conditions, including chronic migraine, excessive sweating and overactive bladder among others, and is Allergan's
-
Size matters?
Clinical trials are ongoing to test its application against overactive bladder and migraine.
-
Astellas sells dermatology unit to Leo for €675m
The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).
More from news
Approximately 4 fully matching, plus 44 partially matching documents found.
Latest Intelligence
-
Astellas: Ten years young
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new
-
Allergan and taking a specialised approach
In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe
-
Interview: Kay Drake and Naoki Okamura, Astellas
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
-
Show stopper exposes taboo
As part of a national campaign called A Matter of Urgency’, the show-stopping garden was designed to raise awareness of Overactive Bladder which affects nearly one in five people in ... Nearly one in five people in the UK over 40 have an overactive
-
Interview: Ken Jones, Astellas Pharma Europe
Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
emotive boosts health economics and outcomes research team
His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- Roche’s Ocrevus boasts positive long-term data in MS
- Leadership change within Bedrock Group
- Lilly starts large-scale trial of tirzepatide in diabetic heart disease
- Havas Health & You Launches Behind the Mask, a Global Research Initiative to Document Health Experiences During the COVID-19 Pandemic and Beyond
- AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain
- BMS eyes approval for second Opdivo combo in kidney cancer
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping
- Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
Quick links
Infographics
